November 18^th at 12:00
Virtual event
Frontiers of Science meets InFLAMES

Prof. Janne Lehtiö, Karolinska Institutet, Sweden
Cancer molecular phenotyping – Leukemia proteomics defined high risk patient populations in CLL and AML
host: Riitta Lahesmaa (rilahes@utu.fi)

Register latest November 17^th at 12:00
https://link.webropolsurveys.com/S/ABF63114770F77AA

Students and early-career postdocs are welcome to share a virtual cup of coffee and discuss with Prof. Janne Lehtiö after the seminar. This is a great possibility to learn hosting skills in friendly environment and create connections for future. Every student are welcome to join, in spite of which research group they belong to.

If you got interested, after registering to the event please send an email to biocityturku@bioscience.fi

Janne Lehtiö has MSc degree in biochemistry from Helsinki University, Finland and PhD in engineering (biotechnology) at Royal Institute of Technology in Stockholm, Sweden. Post the PhD, Lehtiö worked a few years in biotech industry in USA and Europe; and obtained his postdoctoral experience in cancer research at Karolinska Institutet. In 2009, Lehtiö got his assistant professor (docent) merit at Karolinska Institutet and obtained the faculty Professor position 2015. Since 2006, Dr. Lehtiö was appointed as director of the Karolinska University Hospital’s clinical proteomics facility. Currently, Janne Lehtiö is leading a research group of 30 persons at the Department of Oncology-Pathology, KI. He has supervised 15 PhD students and 17 postdoctoral fellows. Lehtiö has a formal university teacher education and is currently lecturing in four graduate programs at KI and is a frequent lecturer at other Swedish universities and internationally.

Dr Lehtiö’s major research interest is in improving human proteome analysis focusing on precision cancer medicine. Lehtiö has 139 peer reviewed original publication and together with his group, he has published number of novel methods for proteome analysis, multi-omics and cancer research applications in leading journals. The Lehtiö-group’s current proteogenomics research focus is on lung and breast cancer as well as on a newly started program on particular childhood and adult leukemia.

Lehtiö has also vast experience on research infrastructures, from heading core facilities and national infrastructure initiatives to expert assignments in the field of technology driven life science. In 2014, he was selected as one of the national research infrastructure fellows by The Swedish Foundation for Strategic Research. Apart for his Scientific Director position in Swedish national bioscience infrastructure, SciLifeLab, Lehtiö also serves in steering board of large national SciLifeLab and KAW Data Driven Life Science (DDLS) program, board of directors in Karolinska Comprehensive Cancer Center and scientific advisory boards for national infrastructures in both Finland (Biocenter Finland) and Norway (NOPI).

General information

• All autumn 2021 Frontiers of Science seminars are arranged online as eTALKs.
• Registration is obligatory and links to register are in BioCity Turku website (https://biocityturku.fi/) and advertised in our news feed.
• For Turku affiliated people it is now possible to register to all autumn 2021 seminars in one go.
• Registration closes and zoom link is sent to participants one day before the event.
• If you are a student and later wish to get a certificate of attendance from the Frontier of Science seminars, please fill in your student number.
• If you wish to follow BioCity Turku news feed and receive up to date information about the Frontiers of Science seminars and other events, please contact biocityturku@bioscience.fi

Please note that any audio or video recording of the seminars is strictly forbidden.